Jefferies & Company Reports on Danaher

Jefferies & Company commented on Danaher DHR in a report released today. In the report, Jefferies was positive in its assessment of the company. Jefferies writes, "FDA closes its Class 1 recall. Beckman Coulter (BEC, $83.28, NC) has achieved a significant milestone in remediating one of the two major quality issues that have been subject to U.S. FDA directives since early-2010. Earlier this week, BEC received a notice from the FDA that its Class 1 recall associated with the ISE flow cells in UniCel DxC platforms (initiated on January 4, 2010) has been closed. According to our estimates, this recall affected ~40% of BEC's U.S. Clinical Chemistry installed base (when including Olympus' installed base) or 5% of total its revenue." Jefferies currently has a Buy rating on Danaher and a price target of $62. Shares of Danaher closed at $52.34 on Thursday.